Therapeutic Response

CD30 + and HER2-negative status confers therapeutic sensitivity to Brentuximab vedotin in combination with Carboplatin, Etoposide, and Ifosfamide in patients with Hodgkin Lymphoma.

Statements

Source and description
Brentuximab vedotin and ICE Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin in combination with ICE (etoposide, carboplatin, and ifosfamide) for reimbursement as a treatment option for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin's lymphoma (HL).